Backgrounds/Aims: En-bloc vein resection (VR) for pancreatic ductal adenocarcinoma (PDAC) of the head of pancreas adherent to the portomesenteric axis benefits patients when the vein wall is not infiltrated by tumour and an R0 resection is achieved, albeit at the expense of greater morbidity and mortality. Methods: A retrospective review of pancreaticoduodenectomy for PDAC over 6 years was conducted. Patients were divided into a standard resection group (Group SR) and simultaneous vein resection group (Group VR) and compared for outcome. Results: The study group consisted of 41 patients (Group SR 15, Group VR 26). VR was performed by end-to-end reconstruction in 12 patients and with interposition grafts in 13 cases (autologous vein in 10, PTFE in 3). R1 resections occurred in 49% patients, with the superior mesenteric artery margin most commonly involved. Patients with Ishikawa grade III and IV vein involvement were more likely to carry a positive SMA margin (p=0.04). Involvement of the splenoportal junction was associated with a significantly greater risk of pancreatic transection margin involvement. No difference in morbidity was seen between the groups. Median survival in the entire group of patients was 17 months and did not vary significantly between the groups. The only significant predictor of survival was lymph node status. Conclusions: Venous involvement by proximal PDAC is indicative of tumor location rather than tumor biology. VR improves outcomes in patients with tumor adhesion to the portomesenteric venous axis despite a high incidence of R1 resections and greater operative mortality. (Ann Hepatobiliary Pancreat Surg 2018;22:261-268)
INTRODUCTION
Fewer than 20% of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) involving the head of the pancreas present with resectable disease. 1 An additional 5-10% of patients present with borderline resectable pancreatic cancer (BRPC) and are likely to benefit from resection after neoadjuvant therapy (NAT). 1, 2 Pancreatic resection with simultaneous resection of the portomesenteric venous axis improves resectability and consequently survival in patients with PDAC with operative morbidity and mortality comparable to standard resections. [3] [4] [5] [6] The benefit is clear and consistent when compared to survival after surgical bypass procedures. 3, 7 It yields maximal benefit in patients with short segment venous involvement 8 and those without histologically demonstrable vein wall infiltration. 6, 9 However, a few reviews have raised concerns that venous involvement by PDAC indicates advanced disease stage 4, 5 and questioned the rationale for this procedure unless the vein wall was free of tumor and R0 resection was achieved. 9 Conventional preoperative imaging is unreliable in predicting vein wall infiltration and determining the need for vein resection (VR). 9, 10 Differentiation between tumor adhesion and infiltration of the vein is unreliable even during surgery. Only about 40% (range 17 to 78%) of patients who undergo VR during pancreatic resection manifest true vein wall infiltration. 6 Nonetheless, Delpero et This study presents the experience of the authors with VR in patients with PDAC of the head of pancreas.
MATERIALS AND METHODS
A retrospective analysis of patients undergoing resection for proximal pancreatic cancer between July 2010
and July 2016 was performed. The study group consisted of all patients with histologically confirmed PDAC following resection. The cohort was divided into two subgroups based on whether or not they underwent VR.
Patients who underwent standard pancreatic resection con- 14 and delayed gastric emptying (DGE). 15 Chylous leaks were diagnosed when drain fluid amylase was normal and drain fluid triglycerides were elevated on a normal diet.
All patients were recommended adjuvant chemotherapy.
Adjuvant radiotherapy was not prescribed for any patient. 
RESULTS
We performed 94 pancreaticoduodenectomies between July 2010 and July 2016, 41 of which were indicated for PDAC and constituted the study group. An additional 7
patients with PDAC did not proceed to resection due to metastatic disease diagnosed at laparoscopy or laparotomy.
The median age of the patients in the study group was 59 years (range: 42-79 years) and included 17 women.
Of these, 5 patients were diagnosed with BRPC and received NAT. Four patients received a gemcitabine-capecitabine combination, and one received FOLFIRINOX 
Operative details of vascular resection
The extent of vein involvement by Ishikawa Classification is described in Table 1 .
Segmental resection was performed in all but one patient who underwent sleeve resection. Reconstruction was carried out via primary anastomosis in 12 patients, interposition autologous left internal jugular vein graft in 10, and interposition PTFE graft in 3 patients. Of the 11 patients with tumor involvement of the splenoportal junction, the SV was ligated in 6, reconstructed to the neo portal vein in 3, and 2 patients underwent total pancreatectomy with splenectomy.
Arterial reconstruction was performed in a patient with limited involvement of the common hepatic artery adjacent to the gastroduodenal artery.
Morbidity, mortality and hospital stay Of the 4 pancreatic fistulae, 3 were Grade A, and 1 was
Grade B requiring percutaneous drainage of an intra-abdominal collection. Of the 5 patients with DGE, all from group VR, 3 were Grade A, and 1 each Grade B and Grade C. One patient underwent re-exploration for bleeding from the mesentery on day 1 after resection in the VR group. Details are provided in Table 2 .
All three deaths occurred in the VR group. One death was attributed to hepatic ischemia in a patient with in- Another patient died from pulmonary sepsis following re-suturing of her abdominal wound for wound dehiscence.
She also had Grade C DGE. The third patient also died from sepsis, the source of which is unclear. However, drain amylase was normal and CT scans did not reveal any intra-abdominal collections. Of the three deaths, two occurred in patients who underwent PTFE reconstruction.
Histopathology
The median maximum tumor diameter of the entire group was 3.6 cm (range 1. Table 1 and 2.
Histological venous invasion was demonstrated in 13 patients (50%), and was significantly more common in patients with Ishikawa III and IV grade venous involvement (p=0.04); it was associated with increasing Ishikawa type ( Log Rank 0.14) (Fig. 3) . No statistically significant difference was found in survival between patients who under- In a meta-analysis, Giovinazzo et al. 6 reported significantly greater overall morbidity (OR 1.34), reoperations (OR 1.4) and postoperative bleeding (OR 1.61) in patients undergoing VR compared with standard resections.
The incidence of pancreatic fistula and DGE was not increased after VR. The mean operative mortality in their analysis was 3.9% in patients undergoing VR and 3% in those undergoing standard resections (p=0.02). Although the overall morbidity in the present series was greater following VR, all the complications in the SR group, and all but one in the VR group were minor. The difference in morbidity was wholly accounted for by the 3 postoperative deaths in the VR group, 2 of which occurred in the 3 patients who underwent PTFE reconstruction.
Since autologous vein graft was the preferred mode of reconstruction by the authors, the use of PTFE may reflect either the need for an unplanned or uncontrolled reconstruction that did not provide enough time for harvesting an autologous vein, or a very long reconstruction.
These situations are known to be associated with increased operative mortality. 8, 18 Factors associated with poor survival post VR include the need for reconstruction longer than 3 cm, 8 true vein wall invasion on histology, 6, 9 and R1 resection. or in other studies. 19 The risk of isolated local recurrence in patients with R1
resections is less than 10%. 20 Evolving consensus suggest that margin involvement might be more indicative of the quality of pathological examination of the resected specimen 21 and tumor biology. 22 A review of specimen histology using the axial slicing technique described by Verbecke et al. 16 revised the R1 resection rate from 14% to 76%, 23 and 53% to 85% 16 respectively, in 2 large independent series even in patients without VR. The importance of tumor biology in the present series is supported by the high rate of R1 resection in the SR group, the fact that 40% of patients with R1 resections had more than one margin involved by tumor, and that survival advantage from R0 resection was not apparent even with tumor-free margins of 1 mm.
SMA margin is the most frequently (15 to 45%) involved margin after VR:, 6 and was involved in 39% of patients in the present series. SMA-first dissection 12 and periadventitial dissection of the SMA 24 are recommended in order to improve the likelihood of R0 resections along this margin, without clear evidence to support. 25 The other commonly involved margin is the pancreatic transection margin (27% in the present series) especially in patients with tumor overlying the splenopancreatic junction. 
